GTCM
LGND icon

Gyon Technologies Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Gyon Technologies Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-5,107
Closed -$232K – 112
2020
Q1 		$232K Buy
+5,107
New +$289K 0.45% 77

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Gyon Technologies Capital Management's LGND Position: Q2 2020 in Review

Gyon Technologies Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2020, closing a stake of 5,107 shares — an estimated $232K sold.

Gyon Technologies Capital Management first reported a position in LGND in Q1 2020 and held it in 1 quarter. The position peaked at $232K in Q1 2020. 262 funds tracked by Wall St. Rank hold LGND as of Q2 2020.

  • Gyon Technologies Capital Management reported no remaining Ligand Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Gyon Technologies Capital Management sold 5,107 Ligand Pharmaceuticals shares in Q2 2020, an estimated $232K.
  • Gyon Technologies Capital Management first reported a position in Ligand Pharmaceuticals in Q1 2020 and held it in 1 quarter.
  • Gyon Technologies Capital Management's Ligand Pharmaceuticals position peaked at $232K in Q1 2020.
  • 262 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2020.

Based on Gyon Technologies Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.